I always thought IONIC would be a hard sell to recruit for compared to DARRT or CEP which are mostly addition to standard of care treatments.
It would take a brave soul to commit to trialling a combination which is trying to work in a place where opdivo alone wouldn't or hasn't. The fact the trial continues does offer hope that some responses have been tallied.
Our new CEO does seem determined to commit to a new CR from the lowest possible price point, either that or she knows more than we do?
IONIC may yet be a winner, page-2
-
- There are more pages in this discussion • 56 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NOX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
11.5¢ |
Change
0.010(9.52%) |
Mkt cap ! $33.60M | |||
| Open | High | Low | Value | Volume |
| 12.5¢ | 14.0¢ | 11.0¢ | $559.0K | 4.481M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6612 | 11.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.0¢ | 99714 | 1 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NOX (ASX) Chart |